- Industry presentation at the AI Theatre: “eyonis™ LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening”
- Median eyonis™ teams will be at booth #AI-18, AI Exhibition, Expo X1
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, today announced that it will attend the European Congress of Radiology (ECR) 2025 in Vienna, from Feb. 26 to March 2.
The Median eyonis™ team will welcome interested parties at Booth #AI-18, AI Exhibition, Expo X1, from February 26 to March 1 (technical exhibits dates). The Company will share the latest developments for eyonis™ Lung Cancer Screening (LCS) Software as a Medical Device (SaMD).
The Company recently reported that eyonis™ LCS, its AI-powered SaMD for Lung Cancer Screening met the primary endpoint with statistical significance in RELIVE, the second of two successful pivotal studies required for marketing authorizations in US and Europe (ClinicalTrials.gov identifier ID NCT06751576). RELIVE secondary endpoints results will be communicated as soon as all the statistical analyses are finalized.
The protocol and primary endpoints for the two pivotal studies, RELIVE and REALITY, were defined in accordance with discussions held with the FDA. By achieving the primary endpoints in both pivotal studies, eyonis™ LCS has successfully completed the regulatory requirements for clinical validation. Consequently, the regulatory dossiers for obtaining the U.S. 510(k) and European CE marking of eyonis™ LCS will be submitted to the agencies in the second quarter of this year.
“The recently reported pivotal study results suggest eyonis™ LCS may enable broad implementation of LDCT lung cancer screening procedures by improving lung cancer diagnosis accuracy and addressing the bottlenecks of complexity and time required for analyzing LDCT images,” said Thomas Bonnefont, COO and CCO of the eyonis™ Business Unit at Median Technologies. “Based on our strong pivotal results, we are now looking towards our filings for marketing authorizations, in both the US and Europe, in Q2 2025, as soon as we finish the analysis. We will report RELIVE secondary endpoints results in the coming weeks. In the interim, we are very pleased to share the eyonis™ LCS pivotal study results already available, and discuss the game changing potential of our Software as a Medical Device with the radiology community at the European Congress of Radiology”, Thomas Bonnefont added.
Median’s eyonis™ team will present at ECR:
- Industry Presentation: “eyonis™ LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening”
Presenter: Valérie Bourdès, MD, VP Clinical and Medical Affairs, eyonis™ – Median Technologies
Session AI-IND 3 – AI Lightning Talks 3
Wednesday, February 26 – 13:30 – 14:30 CET
AI Theatre, ACV Building Level -2
Concurrently, Median’s iCRO team will present:
- Research Presentation : “Discord Dilemmas in Lung Cancer Clinical Trials: Navigating Reader Variability in Response Assessment”
Author: Hubert Beaumont, Lead Scientist, Median Technologies
Research Presentation Session: Oncologic Imaging
Session: RPS 116 – Staging, metastases and response assessment
Wednesday, February 26 – 8:00 – 9:30 CET
ACV Building, Research Stage 3
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
